person · Reporting owner
Courtemanche Craig F. Jr.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PROCORE TECHNOLOGIES, INC.PCOR · Entity 2592 | Director · Chairman of the Board | October 12, 2026 | October 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PROCORE TECHNOLOGIES, INC.
Report date October 12, 2026 · Filed October 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 908,316 |
Ending reported balance
After 2026-10-12 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-10-12 · Exercise / conversion · Acquired 56,122 · Balance 964,438 Row 2 · 2026-10-12 · Sale · Disposed 55,930 · Balance 908,508 F1: These shares sold pursuant to a 10b5-1 plan dated December 9, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold at prices ranging from $55.69 to $56.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2026-10-12 · Sale · Disposed 192 · Balance 908,316 F1: These shares sold pursuant to a 10b5-1 plan dated December 9, 2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.42 · Expires 2026-11-10 | Direct | 0 |
Reported balance
After 2026-10-12 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-10-12 · Exercise / conversion · Disposed 56,122 · Balance 0 F6: The shares subject to the option vested in 60 equal monthly installments beginning on the one month anniversary of February 5, 2016, subject to continued service through each applicable vesting date. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,692,727 |
Reported balance
Holding disclosure · report date 2026-10-12 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 2,692,727 F3: These shares were held by Craig F. Courtemanche and Hillary Courtemanche Family Trust dated as of November 1, 2012. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,155,480 |
Reported balance
Holding disclosure · report date 2026-10-12 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 1,155,480 F4: These shares are held by the Courtemanche 2021 Irrevocable Trust UA DTD 6/10/2021. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 527,349 |
Reported balance
Holding disclosure · report date 2026-10-12 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 527,349 F5: These shares are held by The Courtemanche 2016 Irrevocable Trust. |
| Common StockSEC Table I · non-derivative | IndirectSpouse | 23,736 |
Reported balance
Holding disclosure · report date 2026-10-12 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 23,736 |
Filing footnotes · ownership attribution and instrument terms
F1: These shares sold pursuant to a 10b5-1 plan dated December 9, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold at prices ranging from $55.69 to $56.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: These shares were held by Craig F. Courtemanche and Hillary Courtemanche Family Trust dated as of November 1, 2012.
F4: These shares are held by the Courtemanche 2021 Irrevocable Trust UA DTD 6/10/2021.
F5: These shares are held by The Courtemanche 2016 Irrevocable Trust.
F6: The shares subject to the option vested in 60 equal monthly installments beginning on the one month anniversary of February 5, 2016, subject to continued service through each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 20, 2021 Filed May 24, 2021 21:26 UTC | PROCORE TECHNOLOGIES, INC. PCOR · Entity 2592 | SaleCommon Stock | 122 | $82.64 | $10,082.08 |
DisclosureSEC source: 0001209191-21-035451 · doc4.xml · nonDerivative · entry 1 Courtemanche Craig F. Jr. · CIK 0001805735 · Director · Chief Executive Officer · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 787,927 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.